20180418 AACR 2018 poster PCPV – EN
Category: 2018
TG6002: a novel oncolytic and vectorized gene-prodrug therapy approach to treat glioblastoma
Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation
Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
20180321-Resultats-2017-EN
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
20180315 PR AACR LB poster accepted
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
20180117 PR FPI T101
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
20180116 PR FPI TG4010 1L EN
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
Martin F. Sprinzl, et al. AASLD & Hepatology, October 2017 Download the poster here Poster Presentation
